Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Matcha, a finely ground powder of specially grown and processed green tea leaves, has gained attention for its potential neuroprotective effects, including possible benefits for Alzheimer's Disease (AD). The interest in matcha for AD stems from its high content of catechins, particularly epigallocatechin gallate (EGCG), and other polyphenols with strong antioxidant and anti-inflammatory properties. Scientific studies, primarily preclinical (cell and animal models), suggest that EGCG can inhibit the aggregation of beta-amyloid plaques, a hallmark of Alzheimer's pathology, and may reduce oxidative stress and neuroinflammation in brain tissue. Some epidemiological studies have associated regular consumption of green tea with a reduced risk of cognitive decline, though these studies typically do not isolate matcha specifically from other forms of green tea.

However, robust clinical evidence in humans is lacking. Most clinical trials examining green tea or its extracts in relation to cognitive function have small sample sizes and short durations, with inconsistent results. No large-scale, well-controlled studies have directly tested matcha’s efficacy for preventing or treating Alzheimer's Disease. While the scientific rationale is plausible and preclinical results are promising, the evidence remains preliminary. Therefore, matcha's use for Alzheimer's is justified by emerging, but still limited, scientific research rather than by historical tradition or strong clinical evidence.

More about matcha
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by matcha

Products containing matcha